Edwards Lifesciences Co. (NYSE:EW) Receives $75.67 Average PT from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have earned an average recommendation of “Hold” from the twenty-six ratings firms that are currently covering the stock, Marketbeat reports. Sixteen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $75.67.

EW has been the subject of several recent research reports. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Robert W. Baird cut their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Citigroup dropped their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada reduced their price target on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Edwards Lifesciences Trading Up 0.8 %

NYSE EW opened at $67.54 on Friday. The company has a fifty day moving average of $67.92 and a 200 day moving average of $77.69. The company has a market capitalization of $40.69 billion, a PE ratio of 9.75, a P/E/G ratio of 3.86 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 earnings per share. Research analysts forecast that Edwards Lifesciences will post 2.57 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,250 shares of company stock valued at $1,099,238. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Several institutional investors and hedge funds have recently bought and sold shares of EW. Crewe Advisors LLC acquired a new position in Edwards Lifesciences during the first quarter worth $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $29,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $39,000. Versant Capital Management Inc grew its position in Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares in the last quarter. Finally, HHM Wealth Advisors LLC purchased a new stake in Edwards Lifesciences during the second quarter worth about $55,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.